Olema Oncology Earlier Announced Phase 2 Monotherapy Clinical Study Results For Palazestrant; Showed Results Support Continued Development Of Palazestrant In The OPERA-01 Monotherapy Phase 3 Pivotal Trial

Author: Charles Gross | October 22, 2023 11:11am

Olema Pharmaceuticals, Inc. ((&ldquo, Olema&rdquo, , &ldquo, Olema Oncology&rdquo, , or the &ldquo, Company&rdquo, , NASDAQ:OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, today announced results from a Phase 2 clinical study of palazestrant (OP-1250), the Company’s complete estrogen receptor (ER) antagonist (CERAN) and selective ER degrader (SERD), for the treatment of metastatic ER+/HER2- breast cancer. These results were presented in an oral presentation at the European Society for Medical Oncology (ESMO) Congress 2023 in Madrid, Spain, on October 22, 2023.

• Across all 86 heavily pretreated patients, the median PFS was 4.6 months with a CBR of 40%; in patients with ESR1 mutations at baseline, the median PFS was 5.6 months with a CBR of 52%
• In an analysis of 49 second- and third-line patients, the median PFS was 7.2 months with a CBR of 48%; the median PFS was 7.3 months with a CBR of 59% in patients with ESR1 mutations
• Results support continued development of palazestrant in the OPERA-01 monotherapy Phase 3 pivotal trial
• Olema will host an investor conference call at 8:00 a.m. ET on Monday, October 23, 2023

Posted In: OLMA